Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-000779
Filing Date
2025-02-11
Accepted
2025-02-11 07:00:25
Documents
63
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q epix-20241231x10q.htm   iXBRL 10-Q 1170824
2 EX-31.1 epix-20241231xex31d1.htm EX-31.1 7030
3 EX-31.2 epix-20241231xex31d2.htm EX-31.2 7020
4 EX-32.1 epix-20241231xex32d1.htm EX-32.1 9114
5 GRAPHIC epix-20241231x10q001.jpg GRAPHIC 17235
6 GRAPHIC epix-20241231x10q003.jpg GRAPHIC 38174
7 GRAPHIC epix-20241231x10q004.jpg GRAPHIC 38064
  Complete submission text file 0001558370-25-000779.txt   4793584

Data Files

Seq Description Document Type Size
8 EX-101.SCH epix-20241231.xsd EX-101.SCH 32884
9 EX-101.CAL epix-20241231_cal.xml EX-101.CAL 35023
10 EX-101.DEF epix-20241231_def.xml EX-101.DEF 100075
11 EX-101.LAB epix-20241231_lab.xml EX-101.LAB 273518
12 EX-101.PRE epix-20241231_pre.xml EX-101.PRE 201186
65 EXTRACTED XBRL INSTANCE DOCUMENT epix-20241231x10q_htm.xml XML 639267
Mailing Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5
Business Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5 (778) 331-0962
ESSA Pharma Inc. (Filer) CIK: 0001633932 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37410 | Film No.: 25607645
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)